Gilead Sciences, Inc.
GILD Healthcare Drug Manufacturers General
Gilead Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $29.4 billion, up 2.40% from fiscal 2024. In the quarter to June 2026, revenue grew 10.2%, EPS fell 638.2%, free cash flow grew 376.8% and total debt rose 5.21%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; dividend growth for ten consecutive years.
Follow GILD
Gilead Sciences, Inc. (GILD) Shares outstanding
Gilead Sciences, Inc.'s shares outstanding at the end of fiscal 2025 was $1.3B, unchanged from fiscal 2024. At the end of the quarter to 30 June 2026 it was $1.2B. Over the past ten years it has ranged from $1.3B (fiscal 2025) to $1.5B (fiscal 2015) — the current reading is the lowest in ten years. Gilead Sciences, Inc. ranks 11th of 20 Drug Manufacturers General companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $1.3B | 0.00% |
| FY2024 | $1.3B | (0.24%) |
| FY2023 | $1.3B | (0.32%) |
| FY2022 | $1.3B | 0.00% |
| FY2021 | $1.3B | (0.08%) |
| FY2020 | $1.3B | (1.10%) |
| FY2019 | $1.3B | (2.37%) |
| FY2018 | $1.3B | (0.83%) |
| FY2017 | $1.3B | (2.87%) |
| FY2016 | $1.4B | (10.72%) |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Jun 2026 | $1.2B | (0.88%) |
| Mar 2026 | $1.3B | (0.08%) |
| Dec 2025 | $1.3B | 0.08% |
| Sep 2025 | $1.3B | (0.08%) |
| 42 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| PFE Pfizer Inc. compare | $5.7B |
| NVO Novo Nordisk A/S compare | $4.4B |
| MRK Merck & Co., Inc. compare | $2.5B |
| BMY Bristol Myers Squibb Company compare | $2.0B |
| GSK GSK PLC Sponsored ADR compare | $2.0B |
| NVS Novartis AG compare | $1.9B |
| AZN AstraZeneca PLC compare | $1.6B |
| GILD Gilead Sciences, Inc. | $1.2B |
| AMGN Amgen Inc. compare | $544.0M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on GILD
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement